Owkin closest peer to Pathos

The important point is that Owkin and Pathos are both trying to turn oncology AI from a software feature into a drug development engine. Both start with large multimodal cancer datasets, use AI to decide which patients and assets matter most, and then connect those predictions to real trial and lab work. The split is in operating model. Owkin is built to learn across outside hospitals and labs without centralizing raw data, while Pathos is built to pull those insights directly into its own pipeline decisions and acquisitions.

• Owkin looks peer like because it has the same full stack shape. It combines a federated research network, multimodal and spatial biomarker work, and internal wet lab validation using organoids and other assays. That makes it more than a vendor selling trial software or datasets.
  1 owkin 2 owkin 3 owkin 4 owkin
• Pathos is closer to a biotech that uses AI as its operating system. Its platform ties patient selection, trial design, and asset scouting together, and in May 2026 it used that system to acquire a majority stake in DeuterOncology for a MET inhibitor program identified through Foundry.
  5 pathos 6 pathos
• ConcertAI is adjacent but different. It sells study design optimization, site selection, cohort generation, protocol refinement, and enrollment forecasting to sponsors on top of an oncology data network. Owkin and Pathos go a step further by linking the data layer to biomarker generation, translational work, and program creation.
  7 sacra 8 owkin 1 owkin 5 pathos

This lane is heading toward a small set of oncology companies that own both the learning loop and the development loop. The winners will be the groups that can keep turning patient data into better biomarkers, better trial enrollment, and better asset picks, then feed each result back into the next program faster than traditional biotech teams can.